Clinical Trial Update: Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update for BAX 326 (recombinant factor IX) in Hemophilia B, reporting on pharmacokinetics, efficacy, and safety with completed status and posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 326 (recombinant factor IX)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2013-11-25